<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The relationship between the vasodilating and the hyperbilirubinaemic effect of low and high doses (50 and 300 mg i.v.) of <z:chebi fb="5" ids="15940">nicotinic acid</z:chebi> was studied in baseline conditions and after <z:chebi fb="0" ids="49662">indomethacin</z:chebi> pretreatment in healthy controls and patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> (a condition characterized by fluctuating, nonhaemolytic <z:e sem="disease" ids="C0268306" disease_type="Disease or Syndrome" abbrv="">unconjugated hyperbilirubinaemia</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The hyperbilirubinaemic effect of <z:chebi fb="5" ids="15940">nicotinic acid</z:chebi> was confirmed to be more pronounced in <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> patients than in controls </plain></SENT>
<SENT sid="2" pm="."><plain>The magnitude of <z:e sem="disease" ids="C0020433" disease_type="Disease or Syndrome" abbrv="">hyperbilirubinaemia</z:e> in the two groups was not dependent on the dose of <z:chebi fb="5" ids="15940">nicotinic acid</z:chebi> or <z:chebi fb="0" ids="49662">indomethacin</z:chebi> pretreatment </plain></SENT>
<SENT sid="3" pm="."><plain>A dose-dependent vasodilation which was inhibited by <z:chebi fb="0" ids="49662">indomethacin</z:chebi> could be demonstrated in both controls and <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> subjects </plain></SENT>
<SENT sid="4" pm="."><plain>Vasodilating properties of <z:chebi fb="5" ids="15940">nicotinic acid</z:chebi> were therefore found to be dissociated from the effect on <z:chebi fb="0" ids="16990">bilirubin</z:chebi> </plain></SENT>
</text></document>